--- title: "The Great Unbundling of Hong Kong's Forgotten Tech and Healthcare Stocks" type: "News" locale: "en" url: "https://longbridge.com/en/news/295514635.md" description: "The unclassified tier of the Hong Kong market is undergoing a ruthless polarization in 2026. While infrastructure players and breakthrough biotechs find structural tailwinds, legacy hardware firms faking pivots are facing total marginalization." datetime: "2026-08-11T09:43:53.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295514635.md) - [en](https://longbridge.com/en/news/295514635.md) - [zh-HK](https://longbridge.com/zh-HK/news/295514635.md) generator: "portal-rs" --- # The Great Unbundling of Hong Kong's Forgotten Tech and Healthcare Stocks We spend so much of our days obsessing over the trillion-dollar mega-caps, debating every minor iteration of large language models, that it becomes easy to mistake them for the entirety of the digital economy. But if you want to truly understand the underlying currents of the Hong Kong market in 2026, you have to look down—into the fragmented, unclassified bucket of equities that sit outside the major indices. From telecom data centers to biotech pipelines and obscure hardware makers, these companies are undergoing a quiet but ruthlessly efficient structural reckoning. This matters because the divergence happening in this obscure corner is the real story of the current cycle. In a low-margin-for-error environment, those who can organically capture the tailwinds of the new infrastructure layer are pulling away, while legacy players clinging to outdated business models are facing rapid marginalization. Take the infrastructure layer, for example. As the demand for multi-cloud environments and localized AI compute continues to explode, the bottleneck is steadily shifting from the processors themselves to network interconnectivity. This explains why SUNEVISION (1686.HK) has shown such remarkable counter-cyclical resilience in 2026. The technology flagship of Sun Hung Kai Properties is busy expanding the high-performance networking capabilities of its MEGA-i facility into a broader MEGA Campus. I'm told analysts recently issued significant consensus target upgrades in July 2026, and its stock has broadly outperformed the sector this year. While software startups burn cash searching for elusive AI super-apps, SUNEVISION is quietly securing the most certain business in town: providing the physical floor space and ultra-low latency interconnects required to run the show. And yet... not every company with a "hardware" or "chip" label gets a free ride. The truth, as usual, is more complicated. Just look at Solomon Systech (2878.HK). In mid-July 2026, the display IC supplier issued a brutal profit warning: instead of the USD 4 million profit it posted in the same period of 2025, management expects to log a painful loss of up to USD 4.1 million for the first half of the year. They cited declining terminal demand, escalating R&D expenses, and margin compression exacerbated by RMB appreciation. In a market that had high hopes for their e-paper display business, this is a heavy blow, and its recent market performance heavily reflects that reality. It proves that without monopolistic moats, the cyclical winter in secondary semiconductor markets remains freezing. This tells us that in 2026, capital demands a clear, incremental narrative. That is precisely why NEW VISION (2632.HK) managed to pull off a successful IPO this past March, raising over HKD 717 million against macroeconomic headwinds. The capital markets still have a massive soft spot for automotive OEM electronics, betting on smart vehicles as the next major computing platform. Similarly, former AI voice interaction darling MOBVOI (2438.HK) is fighting to maintain its relevance. As base model price wars intensify, they are under immense pressure to prove their commercial viability beyond early hype. The healthcare sector is seeing an equally stark divide. Late July 2026 finally brought a monumental piece of good news for Lepu Biopharma (2157.HK). Its global Phase III clinical trial for CMG901—a promising antibody-drug conjugate targeting advanced gastric cancer—successfully met its primary endpoint for overall survival. For a biotech company with over 700 employees that has been grinding through the grueling phases of early-stage R&D, this is exactly the kind of catalyst that unlocks massive long-term valuation premiums. Contrast that triumph with the awkward maneuvering of ETHK Labs (1931.HK). Formerly known as IVD Medical Holding, the traditional diagnostic distributor saw its net income completely collapse by 86.6% in 2023. In an attempt to reverse its fortunes, the company rebranded and announced a bold pivot toward an "AI+Healthcare" capital operation platform. It sounds perfectly tailored for a Silicon Valley pitch deck. But seamlessly grafting an AI narrative onto a 30-year-old traditional distribution business? Good luck with that. I hear plenty of deep skepticism from industry insiders regarding the execution. Rebranding isn't rebirth, and investors have largely expressed their lack of trust through a chronically sluggish share price. Then there is the dark side of the moon—the companies that the market has essentially abandoned. You have legacy apparel makers like HP LIVING TECH (1682.HK), drifting far from any modern growth narrative. And then you have a cluster of absolute ghost ships: Wai Chun Group (0147.HK), Trigiant Group (1613.HK), and China Ever Yuan Group (0370.HK). These micro-caps offer virtually zero recent public data, financial updates, or meaningful trading volume. They exist as relics of a bygone era, floating outside the boundaries of an increasingly institutionalized market. My view is this: the long tail of the Hong Kong market in 2026 is undergoing an aggressive and permanent unbundling. Companies with genuine infrastructural necessity or late-stage clinical triumphs are digging wider moats. Meanwhile, those attempting cosmetic pivots, or worse, operating in total opacity, are being systematically and mercilessly priced out. It's harsh, but it's the required path to market maturity. Whoops! *This article does not constitute investment advice.* ### Related Stocks - [01613.HK](https://longbridge.com/en/quote/01613.HK.md) - [01682.HK](https://longbridge.com/en/quote/01682.HK.md) - [01686.HK](https://longbridge.com/en/quote/01686.HK.md) - [01931.HK](https://longbridge.com/en/quote/01931.HK.md) - [02157.HK](https://longbridge.com/en/quote/02157.HK.md) - [02438.HK](https://longbridge.com/en/quote/02438.HK.md) - [02632.HK](https://longbridge.com/en/quote/02632.HK.md) - [02878.HK](https://longbridge.com/en/quote/02878.HK.md) ## Related News & Research - [Goldman Sachs Reaffirms Their Hold Rating on Sunevision Holdings Ltd. (VI6)](https://longbridge.com/en/news/298309939.md) - [SUNeVision expects to rely on HKEX 10% public float rule after SHKP note conversion cuts free float to 15.1%](https://longbridge.com/en/news/298719919.md) - [Jiangsu New Vision Calls EGM to Overhaul Governance and Dividend Policy](https://longbridge.com/en/news/298475666.md) - [SUNeVision proposes new amended and restated memorandum, articles to align with Hong Kong uncertificated securities regime](https://longbridge.com/en/news/297662365.md) - [Sunevision Raises Caps on Connected Property Management Deals to Support Data Centre Expansion](https://longbridge.com/en/news/297667989.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**